Top-line success for AstraZeneca's Brilinta
This article was originally published in Scrip
Executive Summary
AstraZeneca's investigational oral antiplatelet therapy ticagrelor (Brilinta) has met the primary endpoint in a Phase III study comparing it with clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis's (Plavix), the company has announced. The study was designed to see whether ticagrelor is better than clopidogrel in reducing the risk of thrombotic events in acute coronary syndromes (ACS) patients.